Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Galectin Therapeutic (GALT) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 24,110
  • Shares Outstanding, K 29,280
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,030 K
  • 36-Month Beta 1.95
  • Price/Sales N/A
  • Price/Book 6.52
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.49 +81.04%
on 11/03/16
1.10 -19.35%
on 11/16/16
+0.25 (+38.61%)
since 11/02/16
3-Month
0.49 +81.04%
on 11/03/16
3.05 -70.91%
on 09/22/16
-0.81 (-47.82%)
since 09/02/16
52-Week
0.49 +81.04%
on 11/03/16
3.05 -70.91%
on 09/22/16
-1.07 (-54.74%)
since 12/02/15

Most Recent Stories

More News
Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported financial results for the three and nine months...

Research Reports Coverage on Generic Drugs Stocks -- Evoke Pharma, Catalyst Pharma, Neurocrine Biosciences, and Galectin Therapeutics

Stock-Callers.com has initiated coverage on four Generic Drugs companies, namely: Evoke Pharma Inc. (NASDAQ: EVOK), Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), Neurocrine Biosciences Inc. (NASDAQ: NBIX),...

Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia

Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G. Traber, M.D., the company's president,...

Galectin Therapeutics, Inc. to Present at The MicroCap Conference on October 24-25 in Philadelphia

ARLINGTON, VA / ACCESSWIRE / October 11, 2016 / Galectin Therapeutics, Inc. (NASDAQ:GALT) will be presenting at this year's The MicroCap Conference on October 24-25 in Philadelphia at the Hotel Monaco,...

SECFilings Releases Report on Biotech Companies Targeting Liver Disease

REDONDO BEACH, CA--(Marketwired - Oct 7, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published a report on Non-Alcoholic...

SECFilings Releases Report on Biotech Companies Targeting Liver Disease

REDONDO BEACH, CA--(Marketwired - Oct 7, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published a report on Non-Alcoholic...

Galectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic Steatohepatitis

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced it will present two posters that demonstrate...

Downgrade Alert for Galectin Therapeutic (GALT)

Galectin Therapeutic (NASDAQ:GALT) was downgraded from Outperform to Market Perform at FBR Capital today. The stock closed yesterday at $1.15 on volume of 816,000 shares, above average daily volume of...

Downgrade Alert for Galectin Therapeutic (GALT)

Galectin Therapeutic (NASDAQ:GALT) was downgraded from Buy to Neutral at H.C. Wainwright today. The stock closed yesterday at $1.22 on volume of 2.5 million shares, above average daily volume of 165,000....

Downgrade Alert for Galectin Therapeutic (GALT)

Galectin Therapeutic (NASDAQ:GALT) was downgraded from Buy to Sell at Roth Capital today. The stock closed yesterday at $1.40 on volume of 7.8 million shares, above average daily volume of 165,000. ...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Support & Resistance

2nd Resistance Point 0.93
1st Resistance Point 0.89
Last Price 0.88
1st Support Level 0.82
2nd Support Level 0.79

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.